Advisor Group Holdings, Inc. Synlogic, Inc. Transaction History

Advisor Group Holdings, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$0.42 - $0.68 $3,719 - $6,022	8,856 Added 38.7%	31,737 $13,000
Q1 2023 May 12, 2023	BUY	$0.56 - $1.07 $342 - $654	612 Added 2.75%	22,881 $14,000
Q4 2022 Feb 10, 2023	BUY	$0.58 - $17.99 $8,249 - $255,871	14,223 Added 176.77%	22,269 $16,000
Q3 2022 Nov 14, 2022	BUY	$0.91 - $14.63 $2,556 - $41,095	2,809 Added 53.64%	8,046 $8,000
Q2 2022 Aug 10, 2022	BUY	$0.89 - $2.47 $273 - $758	307 Added 6.23%	5,237 $6,000
Q1 2022 May 04, 2022	BUY	$1.63 - $2.55 $101 - $158	62 Added 1.27%	4,930 $12,000
Q3 2021 Nov 05, 2021	BUY	$2.45 - $4.1 $6,524 - $10,918	2,663 Added 120.77%	4,868 $15,000
Q2 2021 Aug 02, 2021	BUY	$3.0 - $4.39 $2,610 - $3,819	870 Added 65.17%	2,205 $9,000
Q1 2021 May 13, 2021	SELL	$2.2 - $5.05 $1,335 - $3,065	-607 Reduced 31.26%	1,335 $5,000
Q4 2020 Feb 10, 2021	BUY	$1.85 - $2.54 $991 - $1,361	536 Added 38.12%	1,942 $4,000
Q3 2020 Nov 12, 2020	BUY	$1.85 - $2.57 $2,601 - $3,613	1,406 New	1,406 $3,000
Q2 2020 Aug 14, 2020	SELL	$1.59 - $2.51 $675 - $1,066	-425 Closed	0 $0
Q1 2020 May 18, 2020	BUY	$1.39 - $3.19 $590 - $1,355	425 New	425 $1,000

25.5K

Ticker SYBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,229,600
Market Cap $103M
Description
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase I...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.